Pollen Typhae total flavone improves insulin resistance in high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats

References

• Romdhane HB, Ali SB, Aissi W, Traissac P, Skhiri Aounnallah H, Bougatef S, Maire B, Delpeuch F, Achour N. Prevalence of diabetes in Northern African countries: the case of Tunisia. BMC Public Health. 2014;14:1–13.
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Developments in diabetes and insulin resistance. Diabetes Care. 2006;29:161–167.10.2337/diacare.29.01.06.dc06-zb01
   PubMed Web of Science ®Google Scholar
• Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J, China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. New Engl. J. Med. 2010;362:1090–1101.10.1056/NEJMoa0908292
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang S, Zhang S. Determination of flavonoids in Pollen Typhae (Puhuang) by HPCE and HPLC. Zhongguo Zhong Yao Za Zhi. 1999;24:682–684, 703. (in Chinese).
   PubMedGoogle Scholar
• Ma HF, Liu B, Zhang GY, Shi RB, Ma CH, Yu MM. GC-MS analysis of the fatty components of Pollen Typhae before and after being carbonized. Zhongguo Zhong Yao Za Zhi. 2006;31:200–202. (in Chinese).
   PubMedGoogle Scholar
• Feng XT, Wang TZ, Chen Y, Liu JB, Liu Y, Wang WJ. Pollen Typhae total flavone improves insulin-induced glucose uptake through the β-arrestin-2-mediated signaling in C2C12 myotubes. Int. J. Mol. Med. 2012;30:914–922.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xue HL, Liu Y, Wang WJ. Yi-Qi-Zeng-Min-Tang, a Chinese medicine, ameliorates insulin resistance in type 2 diabetes. World J. Gastroenterol. 2011;17:987–995.
   PubMed Web of Science ®Google Scholar
• Salman ZK, Refaat R, Selima E, El Sarha A, Ismail MA. The combined effect of metformin and l-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats. Eur. J. Pharmacol. 2013;714:448–455.10.1016/j.ejphar.2013.07.002
   PubMed Web of Science ®Google Scholar
• Zhang M, Lv XY, Li J, Xu ZG, Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rats model. Exp. Diabetes Res. 2008;2008:1–9.
   Web of Science ®Google Scholar
• Karaman A, Bayram F, Gundogan K, Ozsan M, Karaman H, Kelestimur F. Prevalence of diabetes mellitus and glucose metabolism disorders in the first degree relatives of type 2 diabetic patients. Bratisl. Lek. Listy. 2012;113:361–367.
   PubMed Web of Science ®Google Scholar
• Coppey LJ, Holmes A, Davidson EP, Yorek MA. Partial replacement with menhaden oil improves peripheral neuropathy in high-fat-fed low-dose streptozotocin type 2 diabetic rat. J. Nutr. Metab. 2012;2012:1–8.
   Google Scholar
• Ståhlman M, Fagerberg B, Adiels M, Ekroos K, Chapman JM, Kontush A, Borén J. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles. Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids. 2013;1831:1609–1617.10.1016/j.bbalip.2013.07.009
   PubMed Web of Science ®Google Scholar
• Dickson-Humphries T, Bottenberg B, Kuntz S. Lipoprotein abnormalities in patients with type 2 diabetes and metabolic syndrome. J. Am. Acad. Phys. Assist. 2013;26:13–18.
   Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study. Circulation. 2001;104:1108–1113.10.1161/hc3501.095214
   PubMed Web of Science ®Google Scholar
• Feng XT, Wang TZ, Leng J, Chen Y, Liu JB, Liu Y, Wang WJ. Palmitate contributes to insulin resistance through downregulation of the Src-mediated phosphorylation of Akt in C2C12 myotubes. Biosci. Biotechnol. Biochem. 2012;76:1356–1361.10.1271/bbb.120107
   PubMed Web of Science ®Google Scholar
• Ahmed D, Sharma M, Pillai KK. The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats. Fundam. Clin. Pharmacol. 2012;26:621–631.10.1111/fcp.2012.26.issue-5
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl. J. Med. 2007;356:2457–2471.10.1056/NEJMoa072761
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Kaku K, Odawara M, Momomura S, Ishii R. Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks’ treatment, comparative study. Curr. Med. Res. Opin. 2012;28:1007–1016.10.1185/03007995.2012.694361
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang CY, Xu DM, Huang GQ, Xu YL, Wang ZY, Fang SD, Chen Y, Gu YL. The antiatherogenic effects of components isolated from Pollen Typhae. Thromb. Res. 1990;57:957–966.10.1016/0049-3848(90)90162-6
   PubMed Web of Science ®Google Scholar
• Standaert ML, Kanoh Y, Sajan MP, Bandyopadhyay G, Farese RV. Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-lambda, and glucose transport in 3T3/L1 adipocytes. Endocrinology. 2002;143:1705–1716.
   PubMed Web of Science ®Google Scholar